Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of IMVT-1402 in adults with Graves' disease
MOH_2025-11-05_015434Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IMVT-1402 in Graves' disease (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Normalization of thyroid hormone levels with discontinuation of antithyroid drugs. Started Oct 2025; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on MOH_2025-11-05_015434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-05_015434.